Evidence map›Paper›PMID 40357294›Full record

ArticleFrontiers in medicine2025

Impact of aging on alanine aminotransferase levels and frailty in chronic kidney disease patients: laboratory-based cross-sectional study in Northwest Ethiopia.

Melaku Mekonnen Agidew, Anemut Tilahun Mulu, Awgichew Behaile Teklemariam, Misganaw Asmamaw Mengstie, Addisu Melake, Edgeit Abebe Zewde, Zelalem Tilahun Muche, Samuel Berihun Dagnew, Nega Dagnew Baye, Bezawit Adane and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Melaku Mekonnen AgidewDepartment of Biomedical Science, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Anemut Tilahun MuluDepartment of Biomedical Science, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Awgichew Behaile TeklemariamDepartment of Biomedical Science, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Misganaw Asmamaw MengstieDepartment of Biomedical Science, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Addisu MelakeDepartment of Biomedical Science, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Edgeit Abebe ZewdeDepartment of Biomedical Science, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Zelalem Tilahun MucheDepartment of Biomedical Science, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Samuel Berihun DagnewDepartment of Clinical Pharmacy, College of Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia.
Nega Dagnew BayeDepartment of Anatomy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
Bezawit AdaneDepartment of Epidemiology and Biostatistics, School of Public Health, College of Health Sciences, Injibara University, Injibara, Ethiopia.
Muluken WalleDepartment of Hematology and Immunohematology, School of Biomedical and Laboratory Science, College of Medicine and Health Science, University of Gondar, Gondar, Ethiopia.
Girma DersoAmhara Regional State Health Bureau, Bahir Dar, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Chronic kidney disease (CKD) is a non-communicable progressive condition that leads to a gradual decline in kidney functions, resulting in different complications. Serum alanine aminotransferase (ALT) is an important biomarker for diagnosing liver comorbidities. However, ALT levels in CKD patients could be affected by aging. Despite this challenge, there is a scarcity of data on the effect of aging on frailty and ALT levels in CKD patients in Ethiopia. Thus, this study aimed to assess the impact of aging on serum levels of ALT, the magnitude of frailty, and the associated factors among CKD patients in different age groups. Methods: A hospital-based cross-sectional study involving 120 CKD patients was conducted in Bahir Dar, Ethiopia. Data were collected using structured questionnaire. Blood pressure, anthropometric parameters, ALT levels, and frailty were assessed according to standard procedures. Data were analyzed using SPSS version 25. Pearson's correlation analysis, multiple linear analysis, and logistic regression analysis were performed to identify predictors of ALT levels and frailty, with a statistical significance level of Results: The serum level of ALT was significantly lower in CKD patients aged ≥ 46 years compared to CKD patients aged 18-45 years. The magnitude of frailty in CKD patients aged 18-45 and ≥ 46 years was 8.5% (95% CI: 1.4-15.6) and 34.4% (95% CI: 22.5-46.4), respectively, and was significantly associated with ALT levels. Factors such as age category (AOR: 0.16, 95% CI: 0.04-0.60) and hypertension (HTN) (AOR: 10.16, 95% CI: 1.03-99.90) were significantly associated with frailty. Conclusion: The serum level of ALT was significantly correlated with age and frailty in CKD patients. Thus, ALT levels can be used as a biomarker for aging and frailty. The age of CKD patients and HTN were factors significantly associated with frailty.

Indexed as

agealanine aminotransferasechronic kidney diseasesEthiopiafrailty

Identifiers

PMID40357294
PMCPMC12066457

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.